Navigation Links
Cardiome Pharma Corp. Announces Final Results of Tender Offer
Date:10/16/2009

    NASDAQ: CRME    TSX: COM

VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009. Cardiome has accepted 6,470,588 of its common shares for purchase and cancellation at a purchase price of US$4.25 per share (the "Purchase Price"), for an aggregate purchase price of US$27.5 million. The purchased shares represent approximately 9.7% of the outstanding common shares of the Company as of October 13, 2009. Following the cancellation of the common shares purchased under the Offer, 60,163,885 common shares of the Company will remain issued and outstanding.

Based on the final report of the Depository, 7,209,211 common shares were properly tendered to the Offer at or below the Purchase Price. Subject to certain limited exceptions described in the offer to purchase and issuer bid circular for the Offer filed with securities regulatory authorities in Canada and the United States on September 1, 2009, shareholders who tendered their common shares to the Offer at a price equal to or less than the Purchase Price will have approximately 90% of their deposited common shares purchased by the Company. Payment for all common shares accepted for purchase under the Offer will be carried out promptly by the Depository. Because the paid up capital per common share exceeds the Purchase Price, shareholders will not be deemed to receive a dividend upon payment for their common shares.

Common shares tendered to the Offer but not purchased, including common shares deposited at prices greater than the Purchase Price and common shares not purchased because of pro-ration or because the tendering shareholder's minimum conditional tender conditions were not met, will be returned to shareholders as promptly as possible.

Oppenheimer & Co. and Canaccord Capital Corporation (the "Dealer Managers") served as dealer managers for the Offer in the United States and Canada, respectively, and Computershare Investor Services, Inc. (the "Depository") acted as depository.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we, together with our collaborative partners, may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
2. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
3. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
4. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
5. Cardiome to Hold Conference Call
6. Cardiome Announces Management Transition
7. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
8. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
9. Cardiome Reports First Quarter Results
10. Cardiome to Hold Conference Call
11. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology: